Monoclonal antibodies targeting the FimH adhesin protect against uropathogenic E. coli UTI
Science Advances · 20.06.2025 · 11 (25)
DOI: 10.1126/sciadv.adw0698 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 20.06.2025. Verfasst von Edward D B Lopatto und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Microbiology, Washington University in St. Louis, St. Louis, MO, USA. Hauptthemen laut MEDLINE: Adhesins, Escherichia coli, Fimbriae Proteins, Urinary Tract Infections, Uropathogenic Escherichia coli. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Doris Duke Charitable Foundation, NIDDK NIH HHS.
Abstract (Originalsprache)
As antimicrobial resistance increases, urinary tract infections (UTIs) are expected to pose an increased burden in morbidity and expense on the health care system, increasing the need for alternative antibiotic-sparing treatments. Most UTIs are caused by uropathogenic Escherichia coli (UPEC), whereas Klebsiella pneumoniae causes a large portion of non-UPEC UTIs. Both bacteria express type 1 pili tipped with the mannose-binding FimH adhesin critical for UTI pathogenesis. We generated and biochemically characterized 33 murine monoclonal antibodies (mAbs) to FimH. Three mAbs protected mice from E. coli UTI. Mechanistically, we show that this protection is Fc independent and mediated by the ability of these mAbs to sterically block FimH function by recognizing a high-affinity FimH conformation. Our data reveal that FimH mAbs hold promise as an antibiotic-sparing treatment strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular Microbiology, Washington University in St. Louis, St. Louis, MO, USA.
- Center for Women's Infectious Disease Research, Washington University in St. Louis, St. Louis, MO, USA.
- Division of Allergy and Immunology, Department of Medicine, Washington University in St Louis, St Louis, MO, USA.
- Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
- Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, St. Louis, MO, USA.
ORCID-Profile: Edward D B Lopatto, Jesús M Santiago-Borges, Denise A Sanick, Sameer Kumar Malladi, Philippe N Azimzadeh, Morgan W Timm, Aaron J Schmitz, Jackson S Turner, Lillian Ortinau, Nathaniel C Gualberto, Jerome S Pinkner, Ali H Ellebedy, Andrew L Kau, Scott J Hultgren
Förderung
- NIAID NIH HHS
- Doris Duke Charitable Foundation
- NIDDK NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Lopatto, E. D. B., Santiago-Borges, J. M., Sanick, D. A., Malladi, S. K., Azimzadeh, P. N., Timm, M. W., Fox, I. F., Schmitz, A. J., Turner, J. S., Sayed Ahmed, S. M., Ortinau, L., Gualberto, N. C., Pinkner, J. S., Dodson, K. W., Ellebedy, A. H., Kau, A. L., & Hultgren, S. J. (2025). Monoclonal antibodies targeting the FimH adhesin protect against uropathogenic E. coli UTI. Science Advances, 11(25). https://doi.org/10.1126/sciadv.adw0698
Vancouver
Lopatto EDB, Santiago-Borges JM, Sanick DA, Malladi SK, Azimzadeh PN, Timm MW, et al. Monoclonal antibodies targeting the FimH adhesin protect against uropathogenic E. coli UTI. Science Advances. 2025;11(25). doi:10.1126/sciadv.adw0698
BibTeX
@article{Lopatto2025,
author = {Lopatto, Edward D B and Santiago-Borges, Jesús M and Sanick, Denise A and Malladi, Sameer Kumar and Azimzadeh, Philippe N and Timm, Morgan W and Fox, Isabella F and Schmitz, Aaron J and Turner, Jackson S and Sayed Ahmed, Shaza M and Ortinau, Lillian and Gualberto, Nathaniel C and Pinkner, Jerome S and Dodson, Karen W and Ellebedy, Ali H and Kau, Andrew L and Hultgren, Scott J},
title = {Monoclonal antibodies targeting the FimH adhesin protect against uropathogenic E. coli UTI},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {25},
doi = {10.1126/sciadv.adw0698}
}
EUVIMED